Holen Sie sich die Stockscreener-App
0.5252
9.46%
-0.0549
Handel nachbörslich:
.50
-0.0252
-4.80%
Schlusskurs vom Vortag:
$0.5801
Offen:
$0.5745
24-Stunden-Volumen:
380.98K
Relative Volume:
0.33
Marktkapitalisierung:
$5.38M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-31.81%
1M Leistung:
-64.03%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$0.5198
$0.5809
1-Wochen-Bereich:
$0.5198
$0.90
52-Wochen-Spanne:
$0.5198
$2.57
Silexion Therapeutics Corp Stock (SLXN) Company Profile
Firmenname
Silexion Therapeutics Corp
Sektor
Branche
Telefon
972-8-6286005
Adresse
2 HAMAYAN STREET, MODIIN-MACCABIM-REUT
Silexion Therapeutics Corp Aktie (SLXN) Neueste Nachrichten
Silexion Therapeutics Stock Trades Higher, Trial Data For Pancreatic Cancer Patients Shows Promise - MSN
A new trading data show Silexion Therapeutics Corp (SLXN) is showing positive returns. - SETE News
In the Green: Silexion Therapeutics Corp (SLXN) Closes at 0.64, Up/Down -16.28 from Previous Day - The Dwinnex
SLXN’s Market Quandary: Decoding the Ups and Downs of 2023 - The InvestChronicle
Gene Therapy-Focused Bluebird Bio Restructures, Cuts Is Workforce By 25%, Seeks To Breakeven Next Year - Benzinga
Diabetic Kidney Disease Market Revenue to Expand Significantly - openPR
Stock Market Movers Today • Top Gainers & Losers - Benzinga
Silexion Therapeutics Reports Promising Phase 2 Data for Non-Resectable Pancreatic Cancer Treatment - openPR
Silexion Therapeutics Stock Trades Higher, Trial Data For Pancreatic Cancer Patients Shows Promise - Benzinga
Silexion reports improved outcomes in pancreatic cancer trial - Investing.com
Silexion reports improved outcomes in pancreatic cancer trial - Investing.com India
Silexion Therapeutics announces new findings from Loder trial - TipRanks
Stanrose Mafatlal Investments and Finance Limited (STANROS.BO) Latest Stock News & Headlines - Yahoo Finance
Silexion Therapeutics Announces Significant New Data from Phase 2 Trial of LODER™ in Non-Resectable Pancreatic Cancer - Business Wire
Silexion Therapeutics sees board member resignation - Investing.com
Silexion Therapeutics Corp Announces Resignation of Ilan Shiloah as Independent Director, Member of Audit Committee, the Compensation Committee, and the Corporate Governance and Nominating Committee - Marketscreener.com
Emerging Precision Oncology Companies Show Promise Following Summit’s Success - Vancity Buzz
Industry Update: 3 Exciting Precision Oncology Players to Watch - openPR
Industry Update: 3 Exciting Precision Oncology Players to Watch - WICZ
'We've run out of money' says bar owner as venue closes after nine months - Liverpool Echo
Symbotic (NASDAQ:SYM) Shares Gap Up to $22.41 - Defense World
Australia's Sims tops benchmark gains on positive FY25 start - XM
The Potential Rise in the Price of Symbotic Inc (SYM) following insiders activity - Knox Daily
Symbotic (NASDAQ:SYM) Stock Price Up 4.9% - Defense World
Supply@ME Capital (LON:SYME) Sets New 1-Year Low at $0.01 - Defense World
SEGULA Technologies inaugurates new USA headquarters and a Technicon Design studio in Troy, Michigan - WV News
Symbotic (NASDAQ:SYM) Trading Up 1.2% - Defense World
Investor’s Delight: E.W. Scripps Co. (SSP) Closes Strong at 1.95, Up 2.63 - The Dwinnex
Is Spyre Therapeutics Inc. (SYRE) positioned for future growth? - SETE News
Does E.W. Scripps Co. (SSP) offer a good opportunity for investors? - SETE News
Symphera Raises €2.4M in Seed Financing - FinSMEs
Silvis Materials Awarded $1 Million NSF SBIR Phase II Grant to Reduce Emissions in Packaging and Building - EIN News
Stock Traders Buy High Volume of Put Options on Symbotic (NASDAQ:SYM) - Defense World
‘He was brilliant’: Shwab Elementary teachers remember student killed in accidental shooting Saturday night - WSMV 4
Symbotic (NASDAQ:SYM) Shares Gap Up to $22.41 - MarketBeat
Do investors need to be concerned about Spyre Therapeutics Inc. (SYRE)? - US Post News
E.W. Scripps Co. (SSP) did well last session? - US Post News
Régis Le Bris explains Sunderland's Jewison Bennette plan after loan disappointment and position switch - Sunderland Echo
Spyre Therapeutics (NASDAQ:SYRE) Stock Price Down 5% - MarketBeat
Daily Market Movement: Spyre Therapeutics Inc. (SYRE) Sees a 3.23 Increase, Closing at 29.36 - The Dwinnex
Synectics says trading is 'significantly ahead' of previous guidance - Proactive Investors USA
Vertical Research slashes price target on Symbotic Inc [SYM] – find out why. - The DBT News
Research reports, insider buys and stellar earnings have these stocks firing - RagingBull
SLXN: Riding the Market Waves of Growth and Decline in 2023 - The InvestChronicle
Market Momentum: Silexion Therapeutics Corp (SLXN) Registers a 11.61 Increase, Closing at 0.98 - The Dwinnex
Why Oracle Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket - Benzinga
PESG Releases Report on Silexion Therapeutics: Pioneering RNAi Technology in the Fight Against KRAS-Driven Cancers - StockTitan
PESG Releases Report on Silexion Therapeutics: Pioneering RNAi Technology in the Fight Against KRAS-Driven Cancers - Yahoo Finance
Silexion Therapeutics to Present at the H.C. Wainright 26th Annual Global Investment Conference - GlobeNewswire
Silexion Therapeutics to Present at the H.C. Wainright 26th Annual Global Investment Conference - Yahoo Finance
SLXN’s Debt-to-Equity Ratio at 1.32: What It Means for Silexion Therapeutics Corp’s Future - The InvestChronicle
Finanzdaten der Silexion Therapeutics Corp-Aktie (SLXN)
Es liegen keine Finanzdaten für Silexion Therapeutics Corp (SLXN) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
0.05%
4.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):